Topic:

M&A

Latest Headlines

Latest Headlines

PDI gets out of the contracting biz and embraces diagnostics

PDI, which long made its money helping drug companies outsource sales, is shipping off its banner business and shifting its focus to diagnostics.

TPG bets $75M on pharma service provider Precision for Medicine

Private equity giant TPG invested $75 million in Precision for Medicine, a recently formed company that partners with drugmakers to help them establish the value of in-development products.

Sun said to be discussing $2.3B deal for Intas: DealStreetAsia

Sun Pharmaceutical is reported to be in negotiations to buy Indian rival Intas Pharmaceuticals for as much as $2.3 billion, talks that Intas says are not happening.

German generics maker mulls $1.1B sale amid pharma's M&A frenzy: Reuters

It's been a banner year for pharma M&A, and German generics maker Dermapharm is wise to the trend. The company is planning a €1 billion ($1.1 billion) sale, attracting bids from private equity groups that are eager to hop on the dealmaking bandwagon.

Amgen buys another cancer-fighting virus project in a $10.5M deal

Amgen, months removed from a landmark FDA approval in oncology, is buying further into viruses that can hunt and kill cancer within the body.

Ready to step up M&A, Bayer could target big game like Pfizer's OTC unit, Zoetis

Bayer knows it needs more M&A if it wants to keep up in the rapidly consolidating OTC and animal health businesses. But it's not just looking for bolt-on deals.

Indian M&A deals top $1.5B in 2015 led by overseas acquisitions

Overseas acquisitions by Indian drugmakers were at a 5-year high this year and topped $1.5 million compared to just $251 million in 2014, according to a report by Livemint. Using data from VCCEdge, the report said the "sharp increase" in M&A deals was the result of consolidation in the U.S. generics market and a high-risk "appetite" by Indian companies.

Renewed Stryker takeover rumor sends Smith & Nephew stock up

Ever since Zimmer agreed to purchase Biomet for $13.4 billion in April 2014, the wait for takeover of Smith & Nephew has been on, with Stryker being the most likely acquirer. Rumors of an impending deal were just renewed by a StreetInsider report that Stryker has put an $18 billion offer for Smith & Nephew on the table, sending its stock up as much as 6%.

Shire prepared to walk on Baxalta talks if deal doesn't come soon: WSJ

Whether it ends in a tie-up or not, Shire's 6-month pursuit of Baxalta is about to come to a close. That's the word from a Wall Street Journal source close to the deal, who told the newspaper the Dublin drugmaker expects to ink a pact or walk away "reasonably soon."

On the rebound, AMRI trades $52M for a testing firm

AMRI, a contract drugmaker returning to profitability after years of restructuring, bought a New Jersey testing firm for $54 million, expanding its stable of services.
'